Amr A Saad

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. ncbi Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Arthritis Res Ther 11:R52. 2009
  2. ncbi Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Arthritis Care Res (Hoboken) 62:345-53. 2010
  3. ncbi Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Rheumatol 35:883-90. 2008
  4. ncbi Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 49:697-705. 2010

Detail Information

Publications4

  1. ncbi Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, UK
    Arthritis Res Ther 11:R52. 2009
    ....
  2. ncbi Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Arthritis Care Res (Hoboken) 62:345-53. 2010
    ..To evaluate the impact of anti-tumor necrosis factor (anti-TNF) therapies on quality of life (QOL) and functional status in psoriatic arthritis (PsA) patients and study potential predictors for QOL improvements...
  3. ncbi Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    J Rheumatol 35:883-90. 2008
    ..To evaluate the efficacy and safety of tumor necrosis factor-alpha (TNF-alpha) inhibitors in the management of psoriatic arthritis (PsA)...
  4. ncbi Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register
    Amr A Saad
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK
    Rheumatology (Oxford) 49:697-705. 2010
    ..To evaluate the risk-benefit profile of anti-TNF therapies in PsA and to study the predictors of treatment response and disease remission [disease activity score (DAS)-28 < 2.6]...